These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 24162038)

  • 41. Molecular analysis of the SMN1 and NAIP genes in Iranian patients with spinal muscular atrophy.
    Derakhshandeh-Peykar P; Esmaili M; Ousati-Ashtiani Z; Rahmani M; Babrzadeh F; Farshidi S; Attaran E; Sajedifar MM; Farhud DD
    Ann Acad Med Singap; 2007 Nov; 36(11):937-41. PubMed ID: 18071605
    [TBL] [Abstract][Full Text] [Related]  

  • 42. SMN1 deletions among singaporean patients with spinal muscular atrophy.
    Lai AH; Tan ES; Law HY; Yoon CS; Ng IS
    Ann Acad Med Singap; 2005 Jan; 34(1):73-7. PubMed ID: 15726222
    [TBL] [Abstract][Full Text] [Related]  

  • 43. An update of the mutation spectrum of the survival motor neuron gene (SMN1) in autosomal recessive spinal muscular atrophy (SMA).
    Wirth B
    Hum Mutat; 2000; 15(3):228-37. PubMed ID: 10679938
    [TBL] [Abstract][Full Text] [Related]  

  • 44. One Year of Newborn Screening for SMA - Results of a German Pilot Project.
    Vill K; Kölbel H; Schwartz O; Blaschek A; Olgemöller B; Harms E; Burggraf S; Röschinger W; Durner J; Gläser D; Nennstiel U; Wirth B; Schara U; Jensen B; Becker M; Hohenfellner K; Müller-Felber W
    J Neuromuscul Dis; 2019; 6(4):503-515. PubMed ID: 31594245
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Autosomal recessive proximal spinal muscular atrophy in 101 sibs out of 48 families: clinical picture, influence of gender, and genetic implications.
    Rudnik-Schöneborn S; Röhrig D; Morgan G; Wirth B; Zerres K
    Am J Med Genet; 1994 May; 51(1):70-6. PubMed ID: 8030672
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Protocol for a phase II, monocentre, double-blind, placebo-controlled, cross-over trial to assess efficacy of pyridostigmine in patients with spinal muscular atrophy types 2-4 (SPACE trial).
    Stam M; Wadman RI; Wijngaarde CA; Bartels B; Asselman FL; Otto LAM; Goedee HS; Habets LE; de Groot JF; Schoenmakers MAGC; Cuppen I; van den Berg LH; van der Pol WL
    BMJ Open; 2018 Jul; 8(7):e019932. PubMed ID: 30061431
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy of nusinersen in type 1, 2 and 3 spinal muscular atrophy: Real world data from Hungarian patients.
    Szabó L; Gergely A; Jakus R; Fogarasi A; Grosz Z; Molnár MJ; Andor I; Schulcz O; Goschler Á; Medveczky E; Czövek D; Herczegfalvi Á
    Eur J Paediatr Neurol; 2020 Jul; 27():37-42. PubMed ID: 32456992
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comprehensive Mutation Analysis and Report of 12 Novel Mutations in a Cohort of Patients with Spinal Muscular Atrophy in Iran.
    Sharifi Z; Taheri M; Fallah MS; Abiri M; Golnabi F; Bagherian H; Zeinali R; Farahzadi H; Alborji M; Tehrani PG; Amini M; Asnavandi S; Hashemi M; Forouzesh F; Zeinali S
    J Mol Neurosci; 2021 Nov; 71(11):2281-2298. PubMed ID: 33481221
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Spinal Muscular Atrophy: Past, Present, and Future.
    Ross LF; Kwon JM
    Neoreviews; 2019 Aug; 20(8):e437-e451. PubMed ID: 31371553
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Molecular analysis of the spinal muscular atrophy and neuronal apoptosis inhibitory protein genes in Saudi patients with spinal muscular atrophy.
    Al-Jumah M; Majumdar R; Al-Rajeh S; Awada A; Chaves-Carbello E; Salih M; Al-Shahwan S; Al-Subiey K; Al-Uthaim S
    Saudi Med J; 2003 Oct; 24(10):1052-4. PubMed ID: 14578966
    [TBL] [Abstract][Full Text] [Related]  

  • 51. SMN2 and NAIP gene dosages in Vietnamese patients with spinal muscular atrophy.
    Tran VK; Sasongko TH; Hong DD; Hoan NT; Dung VC; Lee MJ; Gunadi ; Takeshima Y; Matsuo M; Nishio H
    Pediatr Int; 2008 Jun; 50(3):346-51. PubMed ID: 18533950
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The Japan Registry for Adult Subjects of Spinal Muscular Atrophy (jREACT-SMA): Protocol for a Longitudinal Observational Study.
    Sahashi K; Hashizume A; Kuwatsuka Y; Chinen M; Saotome-Nakamura A; Ando M; Katsuno M
    JMIR Res Protoc; 2022 Dec; 11(12):e38878. PubMed ID: 36520510
    [TBL] [Abstract][Full Text] [Related]  

  • 53. SMArtCARE - A platform to collect real-life outcome data of patients with spinal muscular atrophy.
    Pechmann A; König K; Bernert G; Schachtrup K; Schara U; Schorling D; Schwersenz I; Stein S; Tassoni A; Vogt S; Walter MC; Lochmüller H; Kirschner J
    Orphanet J Rare Dis; 2019 Jan; 14(1):18. PubMed ID: 30665421
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The analysis of the association between the copy numbers of survival motor neuron gene 2 and neuronal apoptosis inhibitory protein genes and the clinical phenotypes in 40 patients with spinal muscular atrophy: Observational study.
    Zhang Y; He J; Zhang Y; Li L; Tang X; Wang L; Guo J; Jin C; Tighe S; Zhang Y; Zhu Y; Zhu B
    Medicine (Baltimore); 2020 Jan; 99(3):e18809. PubMed ID: 32011487
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Evaluating Benefit-risk Decision-making in Spinal Muscular Atrophy: A First-ever Study to Assess Risk Tolerance in the SMA Patient Community.
    Cruz R; Belter L; Wasnock M; Nazarelli A; Jarecki J
    Clin Ther; 2019 May; 41(5):943-960.e4. PubMed ID: 31056304
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Infantile spinal atrophy: our experience in the last 25 years].
    Madrid Rodríguez A; Martínez Martínez PL; Ramos Fernández JM; Urda Cardona A; Martínez Antón J
    An Pediatr (Barc); 2015 Mar; 82(3):159-65. PubMed ID: 25103837
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical spectrum and diagnostic criteria of infantile spinal muscular atrophy: further delineation on the basis of SMN gene deletion findings.
    Rudnik-Schöneborn S; Forkert R; Hahnen E; Wirth B; Zerres K
    Neuropediatrics; 1996 Feb; 27(1):8-15. PubMed ID: 8677029
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A collaborative study on the natural history of childhood and juvenile onset proximal spinal muscular atrophy (type II and III SMA): 569 patients.
    Zerres K; Rudnik-Schöneborn S; Forrest E; Lusakowska A; Borkowska J; Hausmanowa-Petrusewicz I
    J Neurol Sci; 1997 Feb; 146(1):67-72. PubMed ID: 9077498
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A natural history study of late onset spinal muscular atrophy types 3b and 4.
    Piepers S; van den Berg LH; Brugman F; Scheffer H; Ruiterkamp-Versteeg M; van Engelen BG; Faber CG; de Visser M; van der Pol WL; Wokke JH
    J Neurol; 2008 Sep; 255(9):1400-4. PubMed ID: 18575920
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Disease burden of spinal muscular atrophy in Germany.
    Klug C; Schreiber-Katz O; Thiele S; Schorling E; Zowe J; Reilich P; Walter MC; Nagels KH
    Orphanet J Rare Dis; 2016 May; 11(1):58. PubMed ID: 27145956
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.